Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 503

1.

Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, & Medication Change.

Mahmoud TG, Huang J, Frits M, Iannaccone C, Bykerk V, Bingham CO 3rd, Weinblatt M, Shadick NA.

J Rheumatol. 2019 Jun 15. pii: jrheum.181160. doi: 10.3899/jrheum.181160. [Epub ahead of print]

PMID:
31203222
2.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
3.

Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis.

Gutierrez MJ, Desiderio SV, Wang NY, Darrah E, Cappelli L, Nino G, Jones M, Bingham CO 3rd.

J Immunol Res. 2019 Apr 28;2019:3658215. doi: 10.1155/2019/3658215. eCollection 2019.

4.

Delphi panelists for a core outcome set project suggested both new and existing dissemination strategies that were feasibly implemented by a research infrastructure project.

Akinremi A, Turnbull AE, Chessare CM, Bingham CO 3rd, Needham DM, Dinglas VD.

J Clin Epidemiol. 2019 Jun 5;114:104-107. doi: 10.1016/j.jclinepi.2019.05.026. [Epub ahead of print] No abstract available.

PMID:
31173895
5.

Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Jun 4;20(1):322. doi: 10.1186/s13063-019-3463-8.

6.

Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis.

Heisler AC, Song J, Dunlop DD, Wohlfahrt A, Bingham CO 3rd, Bolster MB, Clauw DJ, Marder W, Phillips K, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Jun 4. doi: 10.1002/acr.23994. [Epub ahead of print]

PMID:
31162824
7.

The Effect of Teenage Passengers on Simulated Risky Driving Among Teenagers: A Randomized Trial.

Simons-Morton BG, Bingham CR, Li K, Zhu C, Buckley L, Falk EB, Shope JT.

Front Psychol. 2019 Apr 30;10:923. doi: 10.3389/fpsyg.2019.00923. eCollection 2019.

8.

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.

Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE.

Arthritis Res Ther. 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1.

9.

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Erratum in: Trials. 2019 Jun 4;20(1):322.

10.

Sonographic findings from inflammatory arthritis due to antisynthetase syndrome.

Miller JB, Danoff SK, Bingham CO 3rd, Paik JJ, Mecoli CA, Tiniakou E, Christopher-Stine L, Albayda J.

Clin Rheumatol. 2019 May;38(5):1477-1483. doi: 10.1007/s10067-019-04471-y. Epub 2019 Feb 27.

PMID:
30810913
11.

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Andersen KM, Kelly A, Lyddiatt A, Bingham CO 3rd, Bykerk VP, Batterman A, Westreich J, Jones MK, Cross M, Brooks PM, March L, Shea B, Tugwell P, Simon LS, Christensen R, Bartlett SJ.

J Rheumatol. 2019 Feb 15. pii: jrheum.181185. doi: 10.3899/jrheum.181185. [Epub ahead of print]

PMID:
30770516
12.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181096. doi: 10.3899/jrheum.181096. [Epub ahead of print]

PMID:
30770515
13.

Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018.

Craig ET, Orbai AM, Mackie S, Bartlett SJ, Bingham CO 3rd, Goodman S, Hill C, Holt R, Leong A, Karyekar C, Leung YY, Richards P, Halls S.

J Rheumatol. 2019 Feb 15. pii: jrheum.181074. doi: 10.3899/jrheum.181074. [Epub ahead of print]

PMID:
30770511
14.

OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies.

Regardt M, Mecoli CA, Park JK, de Groot I, Sarver C, Needham M, de Visser M, Shea B, Bingham CO III, Lundberg IE, Song YW, Christopher-Stine L, Alexanderson H.

J Rheumatol. 2019 Feb 15. pii: jrheum.181065. doi: 10.3899/jrheum.181065. [Epub ahead of print]

PMID:
30770504
15.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 15. pii: jrheum.181097. doi: 10.3899/jrheum.181097. [Epub ahead of print]

PMID:
30770502
16.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.

Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, Clairman H, Bingham CO 3rd, Thornhill S, Strand V, Alongi A, Magni-Manzoni S, van Rossum MAJ, Vesely R, Vojinovic J, Brunner HI, Harris JG, Horton DB, Lovell DJ, Mannion M, Rahimi H, Ravelli A, Ringold S, Ruperto N, Schrandt MS, Shenoi S, Shiff NJ, Toupin-April K, Tzaribachev N, Weiss P, Consolaro A.

J Rheumatol. 2019 Feb 15. pii: jrheum.181088. doi: 10.3899/jrheum.181088. [Epub ahead of print]

PMID:
30770499
17.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Feb 1. pii: jrheum.181218. doi: 10.3899/jrheum.181218. [Epub ahead of print]

PMID:
30709952
18.

Familial interstitial nephritis: 42 years from case series to genetic diagnosis.

Clissold RL, Bingham C, Shaw-Smith C.

Clin Nephrol. 2019 Jun;91(6):386-388. doi: 10.5414/CN109654. No abstract available.

PMID:
30686289
19.

Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O.

Ann Rheum Dis. 2019 Jun;78(6):860-862. doi: 10.1136/annrheumdis-2018-214748. Epub 2019 Jan 18. No abstract available.

PMID:
30659050
20.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck A, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Jan 15. pii: jrheum.181123. doi: 10.3899/jrheum.181123. [Epub ahead of print]

PMID:
30647191
21.

Successful Methotrexate Treatment of Chronic Chikungunya Arthritis.

Amaral JK, Bingham CO 3rd, Schoen RT.

J Clin Rheumatol. 2018 Dec 5. doi: 10.1097/RHU.0000000000000943. [Epub ahead of print] No abstract available.

PMID:
30520824
22.

Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis.

Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA.

Rheumatology (Oxford). 2019 Mar 1;58(3):476-480. doi: 10.1093/rheumatology/key358.

PMID:
30508191
23.

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Darrah E, Giles JT, Davis RL, Naik P, Wang H, Konig MF, Cappelli LC, Bingham CO 3rd, Danoff SK, Andrade F.

Front Immunol. 2018 Nov 20;9:2696. doi: 10.3389/fimmu.2018.02696. eCollection 2018.

24.

Graph-Based Models of Cortical Axons for the Prediction of Neuronal Response to Extracellular Electrical Stimulation.

Bingham CS, Bouteiller JC, Song D, Berger TW.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:1380-1383. doi: 10.1109/EMBC.2018.8512503.

25.

Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis.

DiRenzo D, Crespo-Bosque M, Gould N, Finan P, Nanavati J, Bingham CO 3rd.

Curr Rheumatol Rep. 2018 Oct 18;20(12):75. doi: 10.1007/s11926-018-0787-4. Review.

26.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

27.

Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.

Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L.

J Rheumatol. 2019 Jan;46(1):106-111. doi: 10.3899/jrheum.180353. Epub 2018 Sep 15.

PMID:
30219767
28.

A Glutamatergic Spine Model to Enable Multi-Scale Modeling of Nonlinear Calcium Dynamics.

Hu E, Mergenthal A, Bingham CS, Song D, Bouteiller JM, Berger TW.

Front Comput Neurosci. 2018 Jul 27;12:58. doi: 10.3389/fncom.2018.00058. eCollection 2018.

29.

Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic.

Clissold RL, Fulford J, Hudson M, Shields BM, McDonald TJ, Ellard S, Hattersley AT, Bingham C.

Clin Kidney J. 2018 Aug;11(4):453-458. doi: 10.1093/ckj/sfx150. Epub 2018 Jan 30.

30.

Pain and Catastrophizing in Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study.

Cohen EM, Edwards RR, Bingham CO 3rd, Phillips K, Bolster MB, Moreland LW, Neogi T, Marder W, Wohlfahrt A, Clauw D, Lee YC.

J Clin Rheumatol. 2018 Jun 22. doi: 10.1097/RHU.0000000000000834. [Epub ahead of print]

PMID:
30035754
31.

Genome-wide methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion.

Clissold RL, Ashfield B, Burrage J, Hannon E, Bingham C, Mill J, Hattersley A, Dempster EL.

Clin Epigenetics. 2018 Jul 18;10(1):97. doi: 10.1186/s13148-018-0530-z.

32.

Model-Based Analysis of Electrode Placement and Pulse Amplitude for Hippocampal Stimulation.

Bingham CS, Loizos K, Yu GJ, Gilbert A, Bouteiller JC, Song D, Lazzi G, Berger TW.

IEEE Trans Biomed Eng. 2018 Oct;65(10):2278-2289. doi: 10.1109/TBME.2018.2791860. Epub 2018 Jan 25.

PMID:
29993519
33.

A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation.

Turnbull AE, Dinglas VD, Friedman LA, Chessare CM, Sepúlveda KA, Bingham CO 3rd, Needham DM.

J Clin Epidemiol. 2018 Oct;102:99-106. doi: 10.1016/j.jclinepi.2018.06.007. Epub 2018 Jun 30.

PMID:
29966731
34.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2018 Jul;45(7):1071. doi: 10.3899/jrheum.161252.C2. No abstract available.

PMID:
29961681
35.

Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Wohlfahrt A, Bingham CO 3rd, Marder W, Phillips K, Bolster MB, Moreland LW, Zhang Z, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):521-529. doi: 10.1002/acr.23617.

PMID:
29885039
36.

Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.

Bartlett SJ, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Ginsberg S, Leong AL, Lyddiatt A, Nowell WB, Orbai AM, Smith KC, Bingham CO 3rd.

Qual Life Res. 2018 Sep;27(9):2443-2451. doi: 10.1007/s11136-018-1880-x. Epub 2018 May 24.

PMID:
29797175
37.

Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency.

Gutierrez MJ, Sullivan KE, Fuleihan R; USIDNET Consortium, Bingham CO 3rd.

Semin Arthritis Rheum. 2018 Oct;48(2):318-326. doi: 10.1016/j.semarthrit.2018.02.013. Epub 2018 Feb 23.

PMID:
29599028
38.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

PMID:
29573850
39.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

40.

Global brain dynamics during social exclusion predict subsequent behavioral conformity.

Wasylyshyn N, Hemenway Falk B, Garcia JO, Cascio CN, O'Donnell MB, Bingham CR, Simons-Morton B, Vettel JM, Falk EB.

Soc Cogn Affect Neurosci. 2018 Feb 1;13(2):182-191. doi: 10.1093/scan/nsy007.

41.

Clarification of surface modes of a periodic nanopatch metasurface.

Jia X, Bowen P, Huang Z, Liu X, Bingham C, Smith DR.

Opt Express. 2018 Feb 5;26(3):3004-3012. doi: 10.1364/OE.26.003004.

PMID:
29401833
42.

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Albayda J, Bingham CO 3rd, Shah AA, Kelly RJ, Cappelli L.

Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. doi: 10.1093/rheumatology/kex470. No abstract available.

43.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO 3rd, Ritchlin CT, Schwarz EM.

Nat Rev Rheumatol. 2018 Feb;14(2):94-106. doi: 10.1038/nrrheum.2017.205. Epub 2018 Jan 11. Review.

44.

A practical clinical kinematic model for the upper limbs.

Noble JJ, Fry NR, Bingham CR, East RH, Shortland AP.

Proc Inst Mech Eng H. 2018 Feb;232(2):207-212. doi: 10.1177/0954411917749617. Epub 2017 Dec 28.

PMID:
29283018
45.
46.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2017 Dec;44(12):1944. doi: 10.3899/jrheum.161252.C1. No abstract available.

PMID:
29196552
47.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

48.

Discordance between age- and size-based criteria of child passenger restraint appropriateness.

Smiley ML, Bingham CR, Jacobson PD, Macy ML.

Traffic Inj Prev. 2018 Apr 3;19(3):326-331. doi: 10.1080/15389588.2017.1403016. Epub 2018 Feb 23.

49.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

50.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

Supplemental Content

Loading ...
Support Center